Format

Send to

Choose Destination
Mol Oncol. 2016 Nov;10(9):1430-1436. doi: 10.1016/j.molonc.2016.07.009. Epub 2016 Aug 5.

Concordance between HER-2 status determined by qPCR in Fine Needle Aspiration Cytology (FNAC) samples compared with IHC and FISH in Core Needle Biopsy (CNB) or surgical specimens in breast cancer patients.

Author information

1
Oncologia Medica, Centro Universitario Contra el Cancer, Universidad Autonoma de Nuevo Leon, Mexico.
2
Departement de Biologie et Pathologie Médicales, Gustave Roussy Cancer Campus, Villejuif, France.
3
Service de Biostatistique et d'Epidémiologie, Gustave Roussy Cancer Campus, Villejuif, France.
4
Departement de Biologie et Pathologie Médicales, Gustave Roussy Cancer Campus, Villejuif, France; Laboratoire de Recherche Translationnelle et Centre de Ressources Biologiques, AMMICA, INSERM US23/CNRS UMS3655, Gustave Roussy Cancer Campus, France.
5
Laboratoire de Recherche Translationnelle et Centre de Ressources Biologiques, AMMICA, INSERM US23/CNRS UMS3655, Gustave Roussy Cancer Campus, France.
6
Departement de Médecine, Gustave Roussy Cancer Campus, Villejuif, France.
7
Service des Opérations de Recherche Clinique, Gustave Roussy Cancer Campus, Villejuif, France.
8
Service de Biostatistique et d'Epidémiologie, Gustave Roussy Cancer Campus, Villejuif, France; INSERM U1018, CESP, Université Paris-Sud, Université Paris-Saclay, Villejuif, France.
9
Departement de Médecine, Gustave Roussy Cancer Campus, Villejuif, France; INSERM U981 et Université Paris-Sud, Université Paris-Saclay, Villejuif, France.
10
Departement de Biologie et Pathologie Médicales, Gustave Roussy Cancer Campus, Villejuif, France; Laboratoire de Recherche Translationnelle et Centre de Ressources Biologiques, AMMICA, INSERM US23/CNRS UMS3655, Gustave Roussy Cancer Campus, France. Electronic address: philippe.vielh@gustaveroussy.fr.

Abstract

Determining the status of HER2-neu amplification and overexpression in breast cancer is crucial for prognosis but mostly for treatment purposes. Standard techniques include the determination of IHC in combination with in situ hybridization techniques to confirm a HER2-neu amplification in case of IHC2+ using either a core-needle biopsy or a surgical specimen. qPCR has been also demonstrated to be able to determine HER2 status, mostly in core biopsies or in surgical specimens. Fine-needle aspiration is a reliable, quicker and less invasive technique that is widely used for diagnosis of invasive breast cancer. In this study, we assessed the performance of qPCR in invasive breast carcinomas to determine HER2-neu status by using fine-needle aspiration samples and comparing to standard IHC and FISH. From a total of 154 samples from patients who had nodular breast lesions and attended the 1-day-stop clinic at the Gustave Roussy from March 2013 to October 2014, qPCR was able to determine the HER2 status in a mean of 3.7 days (SD 3.1). The overall concordance with standard HER2-testing was very high: 97% (95% CI 0.94 to 0.99); sensitivity was 96% (0.87-1), specificity 98% (0.95-1) and positive and negative predictive values 88% (0.75-1) and 99% (0.98-1), respectively. In conclusion, our study demonstrates that qPCR performed using fine-needle aspiration samples from a primary tumour is a reliable and fast method to determine HER2/neu status in patients with early breast cancer.

KEYWORDS:

Breast cancer; Cytology; Fine needle aspiration; HER2; qPCR

PMID:
27555543
PMCID:
PMC5423214
DOI:
10.1016/j.molonc.2016.07.009
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center